These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 19793678

  • 1. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP.
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [Abstract] [Full Text] [Related]

  • 2. Predicting recurrence-free survival after surgery for GIST.
    Joensuu H.
    Lancet Oncol; 2009 Nov; 10(11):1025. PubMed ID: 19793677
    [No Abstract] [Full Text] [Related]

  • 3. Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients.
    Chok AY, Goh BK, Koh YX, Lye WK, Allen JC, Quek R, Teo MC, Chow PK, Ong HS, Chung AY, Wong WK.
    Ann Surg Oncol; 2015 Oct; 22(11):3597-605. PubMed ID: 25652053
    [Abstract] [Full Text] [Related]

  • 4. Risk stratification systems for surgically treated localized primary Gastrointestinal Stromal Tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogramm, NIH-Fletcher and AFIP-Miettinen.
    Belfiori G, Sartelli M, Cardinali L, Tranà C, Bracci R, Gesuita R, Marmorale C.
    Ann Ital Chir; 2015 Oct; 86(3):219-27. PubMed ID: 26098671
    [Abstract] [Full Text] [Related]

  • 5. Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study.
    Bertsimas D, Margonis GA, Sujichantararat S, Koulouras A, Ma Y, Antonescu CR, Brennan MF, Martín-Broto J, Tang S, Rutkowski P, Kreis ME, Beyer K, Wang J, Bylina E, Sobczuk P, Gutierrez A, Jadeja B, Tap WD, Chi P, Singer S.
    Lancet Oncol; 2024 Aug; 25(8):1025-1037. PubMed ID: 38976997
    [Abstract] [Full Text] [Related]

  • 6. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
    Li J, Gong JF, Wu AW, Shen L.
    Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
    [Abstract] [Full Text] [Related]

  • 7. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H.
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [Abstract] [Full Text] [Related]

  • 8. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
    Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.
    J Clin Oncol; 2014 May 20; 32(15):1563-70. PubMed ID: 24638003
    [Abstract] [Full Text] [Related]

  • 9. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.
    Eur J Cancer; 2014 Jul 20; 50(10):1772-1778. PubMed ID: 24768330
    [Abstract] [Full Text] [Related]

  • 10. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
    Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, Mcarthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P.
    Eur J Cancer; 2015 May 20; 51(7):852-60. PubMed ID: 25801699
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG.
    BMC Gastroenterol; 2014 Jun 07; 14():105. PubMed ID: 24906683
    [Abstract] [Full Text] [Related]

  • 12. A nomogram to predict disease-free survival after surgical resection of GIST.
    Bischof DA, Kim Y, Behman R, Karanicolas PJ, Quereshy FA, Blazer DG, Maithel SK, Gamblin TC, Bauer TW, Pawlik TM.
    J Gastrointest Surg; 2014 Dec 07; 18(12):2123-9. PubMed ID: 25245766
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton TL, Billingsley KG, Johnson AJ, Corless CL, Blanke CD, Heinrich MC, Mayo SC.
    J Surg Oncol; 2024 Jul 07; 130(1):40-46. PubMed ID: 38924626
    [Abstract] [Full Text] [Related]

  • 14. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.
    Ann Surg; 2013 Sep 07; 258(3):422-9. PubMed ID: 23860199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
    Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP.
    Am J Surg Pathol; 2011 Nov 07; 35(11):1646-56. PubMed ID: 21997685
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Gold's nomogram for predicting recurrence-free survival in gastrointestinal stromal tumors in Indian patients.
    Valappil FK, Rajan R, Natesh B, Sindhu RS, Raviram S, Mathew J.
    Indian J Gastroenterol; 2016 May 07; 35(3):225-8. PubMed ID: 27256432
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep 07; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
    Li Y, Meng X.
    Ann R Coll Surg Engl; 2015 Apr 07; 97(3):215-20. PubMed ID: 26263807
    [Abstract] [Full Text] [Related]

  • 20. Developed and validated a prognostic nomogram for recurrence-free survival after complete surgical resection of local primary gastrointestinal stromal tumors based on deep learning.
    Chen T, Liu S, Li Y, Feng X, Xiong W, Zhao X, Yang Y, Zhang C, Hu Y, Chen H, Lin T, Zhao M, Liu H, Yu J, Xu Y, Zhang Y, Li G.
    EBioMedicine; 2019 Jan 07; 39():272-279. PubMed ID: 30587460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.